The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Academy Medal Recipients
Eminent Fellows
Eminent Fellows

The Eminent Fellowships are awarded based on significant contribution in the field of pharmaceutical science and Eminent Fellows provide the APSGB Board with advice and guidance on topics within their area of expertise. These are prestigious awards and it is rare for one institution to get such recognition.
Eminent Fellows
Prof Graham Buckton
Graham Buckton graduated with a BPharm degree from Chelsea College London in 1981. He obtained his PhD from King’s College London in 1985 and was awarded the degree of Doctor of Science by the University of London in 1997, for “Materials characterisation of importance to drug delivery”. In 2012 he passed the IoD Certificate in Company Direction. Professor Buckton is a fellow of the Royal Pharmaceutical Society, Royal Society of Chemistry, AAPS and APSGB, he is a Freeman of the City of London. He joined the staff of King’s College London as lecturer in pharmacy in 1984. In 1989 he moved to the School of Pharmacy, University of London where he progressed through the positions of Lecturer, Senior Lecturer, Reader and Professor and was the Head of Department and Professor of Pharmaceutics. Until Sept 2012 he was Chief Executive Officer of Pharmaterials Ltd which is the contract research company that he founded in 2000. He retains a research group at the UCL School of Pharmacy, University of London. The research relates to the amorphous state, powder processing, surface science, solid oral dosage forms, inhalation drug delivery and modified release dosage forms. He has published a book and over 175 papers on these themes. He has received the Pfizer Award, the British Pharmaceutical Conference Science Medal and the Stig Sunner Award (for “outstanding work in Thermochemistry and Thermal Analysis” from the US Calorimetry Conference). He • Has served a 10 year term as Editor of the International Journal of Pharmaceutics and has recently served, on the editorial boards of Pharmaceutical Research, The AAPS Journal and the steering committee for the Excipients Handbook. • Was the first Chairman of the Academy of Pharmaceutical Sciences of GB and a past Chairman of the Pharmaceutical Sciences Group of the Royal Pharmaceutical Society of Great Britain, • Was past Chairman of the Chemistry, Pharmacy and Standards sub-committee of the Committee on Safety of Medicines and a member of the CSM, is a member of the CPS TAG of the Commission on Human Medicines. • Was Science Chairman of the British Pharmaceutical Conference 2003. • Was a British Pharmacopoeia Commissioner and contributes to Ph Eur, USP and EMEA working parties.
Prof Donald Cairns
Donald Cairns obtained a Bachelor of Science degree in pharmacy from the University of Strathclyde in 1980 and after a pre-registration year spent in hospital pharmacy, returned to Strathclyde to undertake a PhD on the synthesis and properties of benzylimidazolines. Following a year as a post-doctoral research fellow in the department of Pharmacy at Sunderland Polytechnic (now the University of Sunderland), Dr Cairns moved to Leicester Polytechnic (now De Montfort University) where he held a five-year lectureship in Pharmacy. In 1992 Dr Cairns was appointed senior lecturer in medicinal chemistry in Sunderland School of Pharmacy and in 2003 moved to The Robert Gordon University in Aberdeen as Associate Head of the School of Pharmacy. In 2006, he was promoted to Professor of Pharmaceutical and Medicinal Chemistry at RGU and in 2010 was appointed Acting Head of the School of Pharmacy & Life Sciences. Prof Cairns has authored over 50 peer reviewed research papers and has research interests include the design and synthesis of selective anticancer agents, the molecular modelling of drug / DNA interactions and the design of prodrugs for the treatment of nephropathic cystinosis. Donald Cairns is registered with the General Pharmaceutical Council, and is a Fellow of the Royal Society of Chemistry in addition to serving as a Board member of the Association of Pharmaceutical Scientists. In 2006 he was appointed to the British Pharmacopoeia Commission and serves on an Expert Advisory Group of the Commission on Human Medicines.
Prof Roger Davey
Roger Davey joined the department in 1993 as Professor of Molecular Engineering. He previously worked as a Research Associate for Zeneca and prior to that with ICI. In 2001 Roger was awarded an EPSRC Senior Research Fellowship to pursue his research on nucleation of molecular materials. In 2002 he founded the Molecular Materials Centre and in now a key figure in the Knowledge Centre for Materials Chemistry funded through the NWDA. Roger's research activities involve the application of crystal chemistry to the design of inorganic and molecular materials as well as surface active molecules. This is an important field both academically and commercially. For example, such areas as crystal morphology and structure control by the use of specifically tailored auxilliary molecules together with the design of crystallisation inhibitors and other surface active molecules are of fundamental importance across a range of technologies from catalyst manufacture through a wide spread of speciality businesses. Of current interest are the areas of polymorphism in molecular crystals, the preparation of materials via crystallisation within surfactant phases, the application of ternary phase diagrams in process design for preparation of molecular salts and cocrystals, the formation and properties of crystal networks in consumer products and molecular modelling of crystals and surfaces. Significant work is being performed using spectroscopies to study solution chemistry and molecular association in supersaturated solutions in the context of crystal nucleation.
Prof Martyn Davies
I qualified as a Pharmacist, graduating top of my year with First Class Honours and gained my PhD from the Chelsea School of Pharmacy (now Kings College) under the supervision of Mike Newton. After a year at the Manchester School of Pharmacy covering John Fell's sabbatical leave in 1984, I was appointed to a lectureship at Nottingham in 1985. I was promoted to Reader in 1991 and then to a personal Chair in 1996. During this period, I was also Head of Life, Health & Agricultural Sciences Division, Graduate School (1995-97). I was Head of School of Pharmacy from 2000 - 3. I am the cofounder (with Saul Tendler) and until Jan 2008, was Head of the Laboratory of Biophysics and Surface Analysis (LBSA), a Research Division of the School of Pharmacy, ( The LBSA has an international leading reputation and track record in scanning probe microscopy and surface chemical analysis of pharmaceuticals, polymers and biomaterials. The LBSA remain the only grouping to receive the GlaxoSmithKline International Achievement Award (2003), given for "internationally recognized work on drug delivery and new techniques for surface and interface analysis". I have been involved with the formation of a number of University spin-out companies and I am the co-founder and Chairman of a successful spin-out from the LBSA, Molecular Profiles Ltd ( which was awarded the Queens Award for Enterprise in the category of Innovation in 2007. My work has led to a number of prizes including the CRS Young Investigator Award (1997) and the Distinguished Service Award of the CRS (2008). I was the Scientific Secretary of the CRS (2001-7), was a participant in the recent ESF Forward Look on Nanomedicine, have recently been re-elected to the EPSRC Peer Review College and am a member of the RAE 2008 Pharmacy Panel. I have organised numerous international scientific conferences and am on the editorial boards of 4 science journals. I am a Fellow of the Royal Society of Chemistry, American Institute of Biological Engineering and Royal Pharmaceutical Society of Great Britain.
Prof Bill Dawson
Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years service and established Bionet Ltd as a health care consultancy working at the interface between academia and industry. At Lilly, Bill was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Latterly, he was Director of Technology Acquisition, Europe, for Lilly. He continues to be a member of the ABPI Academic Liaison Working Group. He is Director of the University of Manchester Medicines Network. He is a non-executive director of Proteome Sciences plc, Antitope Ltd, Pharmovation Ltd and a member of a number of corporate Scientific Advisory Boards. Previously, he was a Director of Biovation Ltd, purchased by Merck KGaA, Enzacta Ltd, merged to form Enact Pharma Ltd and now part of Protherics plc and the Babraham Institute where he served the maximum two terms. He was a Board Member of the Pharmaceutical Licensing Group from 1994-2005. PLG is the professional organisation representing the majority of licensing executives in the UK. He has been active in peer review for MRC, EPSRC and BBSRC and has participated in a number of DTI grant and review panels. He is a Visiting Professor in the School of Science and Mathematics at Sheffield Hallam University and is a Governor of the University of Brighton and of De Montfort University. He is a Fellow of the School and was previously a member of staff in the pharmacology department having completed his PhD at the School under Professor Geoffrey B West Professor Dawson qualified as a pharmacist and specialised in pharmacology. His research interests are in immunopharmacology and in the rational design, selection and progression of new medicines through optimal research and development programmes.
Prof Ruth Duncan
Until Sept 2008 Ruth Duncan was Director of the Centre for Polymer Therapeutics at the Welsh School of Pharmacy, Cardiff University, UK. She is currently holds the honorary positions of Professor Emerita in Cardiff University, and Visiting Professor at the University of Greenwich and Centro de Investigación Príncipe Felipe, Valencia. She is also a member of a number of Institutional and International Advisory Boards and Committees. In September 2010 she was awarded an honorary doctorate from the University of Mainz.
Prof Gillian Eccleston
Prof Gregory Gregoriades
Professor Gregory Gregoriadis is Xenetic's Chief Scientific Officer. In 1997 he founded Xenetic (then known as Lipoxen) as a spin out from The School of Pharmacy, University of London, where he was Head of the Centre for Drug Delivery Research. Prior to this, Professor Gregoriadis was Head of the Liposomal Therapeutics Group at the Medical Research Council. He is an internationally acknowledged expert in drug and vaccine delivery. In 1971, he was the first to introduce liposomes as vehicles for drug and vaccine delivery and in 1991 he introduced the use of polysialic acid as a means to improve the pharmacological action of peptide and protein drugs. He has published nearly 400 research papers, reviews and articles, as well as 27 volumes on drug delivery and targeting. Professor Gregoriadis’ achievements have been honoured with the Controlled Release Society Founders Award (1994), the A.D. Bangham FRS Life Achievement Award (1995), election as a Fellow of the American Association of Pharmaceutical Scientists (1998), a DSc from the University of London (2001) and The Journal of Drug Targeting Life Achievement Award (2008) all for exceptional contributions to the field of drug and vaccine delivery. Professor Gregoriadis’ seminal contributions to the field of drug and vaccine delivery are also reflected in his founding in 1978 of the on-going Gordon Research Conference series 'Drug Carriers in Medicine and Biology', his directorships of the NATO Advanced Studies Institute's 'Targeting of Drugs and Vaccines' from 1981 until 1999, his Chairmanship of the 'Liposome Advances' conference series from 1990 until 2006 and his position as Emeritus Professor at the University of London. Since 2003 Professor Gregoriadis has been President of the International Liposome Society.
Prof Richard Guy
Richard Guy received an M.A. in Chemistry from Oxford University, and his Ph.D. in Pharmaceutical Chemistry from the University of London. He has held academic posts at the University of California, San Francisco and the University of Geneva. In 2004, he joined the University of Bath as Professor of Pharmaceutical Sciences, and he currently serves as the Chair of the Research Committee of the Department of Pharmacy & Pharmacology. Dr. Guy is an elected fellow of the Academy of Pharmaceutical Scientists, Great Britain, the Royal Society of Chemistry, the Controlled Release Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science.
Prof Jonathan Hadgraft
Prof Trevor Jones CBE FMedSci
Professor Jones is a Director of a number of International Pharmaceutical Companies including Allergan Inc (USA) and Sigma Tau (Italy and USA) He was formerly Group R&D Director and The Wellcome Foundation and Director General of the Association of the British Pharmaceutical Industry (ABPI) He is a visiting professor at King’s College, London and holds honorary degrees and Gold Medals from 6 universities. He has served in various government /international organisation capacities such as a Commissioner for the World Health Organisation (WHO) a member of The UK Government regulatory agency …The Medicines Commission…advisor to the Cabinet Office on the Human Genome project; a member of the Prime Minister’s Task force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the UK Government Advisory Group on Genetics Research.
Prof David Jones
Professor David Jones is currently he Pro-Vice-Chancellor for Education and Students within Queen’s University Belfast. He has a BSc Pharmacy from Queen’s, and a PhD and DSc both from Queen’s. David started his academic career in 1988 at the University of Otago as a Lecturer in Pharmaceutical Technology and then moved to Norbrook Laboratories to gain Industrial experience. David then returned to Academia in 1994, taking up a Lectureship within QUB. Within QUB he quickly rose through the ranks and gained his personal Chair in Biomaterials in 1999. David has held a number of senior leadership roles and awards including Head of School, Royal Society Industrial Fellow, Eli Lilly Award for Pharmaceutical Excellence and BPC Science Medal. He also holds a number of external roles including Editor of the Journal of Pharmacy and Pharmacology, co-Editor of Drug Delivery and UKPharmSci Science Chair (2015).
Prof Jayne Lawrence
Jayne is Professor and Head of the Pharmaceutical Biophysics Group. She is currently on a 50% secondment at the Royal Pharmaceutical Society (RPS) as their Chief Scientist. At the RPS Jayne is responsible for science and research, performing a variety of roles including working with other scientific organisations and the media and ensuring that the RPS and its membership is up to date with the latest scientific developments in pharmacy. This is a role she has performed since 2007. At King’s, Jayne’s research has focussed on improving the delivery of low molecular weight drugs and biomolecules such as DNA and siRNA using a range of novel and conventional surfactant/polymer and lipid molecules. Jayne is particularly interested in understanding how the structure of a molecule influences the molecular architecture of the delivery vehicle it forms and its fate in the target cell. To achieve these aims Jayne uses a range of advanced analytical techniques including light and neutron scattering and reflectivity. Jayne sits on a number of national committees including the Academy of Pharmaceutical Sciences (Vice-Chair), the United Kingdom and Ireland Controlled Release Society (Treasurer) and the Joint Pharmaceutical Analysis Group, the Institute of Physics and Royal Society of Chemistry’s Joint Neutron Group. She has recently been appointed Vice-Chair of the Formulation and Pharmaceutical Technology Special Interest Group for the International Pharmaceutical Federation. Jayne is a pharmacist, having completed a BSc in Pharmacy at Liverpool Polytechnic and undertaken a year’s pre-registration training in community and industrial pharmacy. After qualifying as a pharmacist Jayne undertook a PhD at Manchester University under the supervision of Professors Peter Elworthy and David Attwood. Jayne started her academic career as a lecturer in Pharmacy at Chelsea College, which subsequently merged with King’s College. Jayne has spent sabbaticals working in the pharmaceutical industry and retains excellent links with the industry.
Prof Tony Moffat
Tony is Professor of Pharmaceutical Analysis at The School of Pharmacy, University of London where he heads the Centre for Pharmaceutical Analysis. The Centre provides a focus for research and education in pharmaceutical analysis within The School and is extending the world-class knowledge base in that field. In particular, Near-Infrared Spectroscopy is being used: to further the technique, increase its use in the pharmaceutical industry and get it accepted by the regulatory authorities. He was previously Chief Scientist at the Royal Pharmaceutical Society of Great Britain where he gave advice on scientific matters to the Society’s Council and other departments within the Society. Part of his duties was to write policy papers concerning the scientific aspects of pharmaceutical health care and how it may be delivered to the community at large. He has extensive knowledge at first-hand of pharmacy in the community, academic and hospital settings, and has excellent links to the pharmaceutical industry. He also acted as the Society’s scientific spokesperson for the media. He has over 300 publications as well as the co-authorship of 7 books (including Clarke’s Analysis of Drugs and Poisons). His awards include the British Pharmaceutical Conference Science Award, Society of Analytical Chemistry Silver Medal, Philip Allen Award of the Forensic Science Society, joint award of the BUCHI 2002 Award, the Academy of Pharmaceutical Sciences Medal and the Royal Pharmaceutical Society’s Charter Gold Medal. Tony is currently a member of a number of Committees including the British Pharmacopoeia Commission.
Prof Yvonne Perrie
Professor Yvonne Perrie is Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Scotland. She has a BSc (First-Class Hons) in Pharmacy from Strathclyde University, and a PhD from the University of London under the supervision of Prof Gregoriadis. Yvonne’s research is multi-disciplinary and focused on the development of drug carrier systems for the delivery of drugs and vaccines. Yvonne is Editor-in-Chief of the Journal of Liposome Research and Pharmaceutics and Associate Editor for the Journal of Drug Targeting and the Journal of Pharmacy and Pharmacology.
Prof Thomas Rades
Since March 2012 Professor Thomas Rades is the Research Chair in Pharmaceutical Design and Drug Delivery in the Department of Pharmacy, University of Copenhagen. Before that he has been the Chair in Pharmaceutical Sciences at the National School of Pharmacy, University of Otago, New Zealand from 2003 – 2012. In 1994 he received a PhD from the University of Braunschweig, Germany for his work on thermotropic and lyotropic liquid crystalline drugs. After working as a Research Scientist in the Preclinical Development and Formulation at F. Hoffmann-La Roche in Basel, Switzerland, he became a Senior Lecturer in Pharmaceutical Sciences at Otago in 1999 and since 2003 held the Chair in Pharmaceutical Sciences in Otago. Professor Rades has developed an international reputation for his research in the physical characterization of drugs solid dosage forms as well as in vaccine delivery using nanoparticulate systems (both polymeric and lipid based). Prof Rades has published more than 275 papers in international peer review journals as well as several book chapters and patents and one book. Prof Rades is an Editor of the Journal of Pharmaceutical Sciences and the European Journal of Pharmaceutics and Biopharmaceutics and an Associate Editor of the Journal of Pharmacy and Pharmacology. He holds an honorary doctorate of Åbo Akademie University, Finland, a visiting professorship at the Department of Medicine at the University of Adelaide, Australia and an honorary professorship at the University of Otago, New Zealand. He is an Eminent Fellow of the Academy of Pharmaceutical Sciences (UK) and a Fellow of the New Zealand Institute of Chemistry. Professor Rades has successfully supervised more than 50 PhD students. For his undergraduate and postgraduate teaching he was awarded the New Zealand Tertiary Teaching Excellence Award for Sustained Excellence (2005). His research interests include The solid state of drugs and dosage forms, and Nanoparticles as delivery systems for drugs and vaccines. Research in both areas aims to improve drug therapy through appropriate formulation and characterisation of medicines and to increase understanding of the physico-chemical properties of drugs and medicines. It combines physical, chemical, and biological sciences and technology to optimally formulate drugs and vaccines for human and veterinary uses.
Dr Ali Rajabi-Siahboomi
Dr Rajabi-Siahboomi has both a B. Pharm. and Ph.D. in Pharmacy from Nottingham University. His Ph.D. thesis focused on hydrophilic matrices and formulation factors affecting drug release, under different dissolution conditions. He expanded his research area beyond the extended release matrices to include other aspects of pharmaceutical platforms and technologies, when he moved to Liverpool John Moores University as a lecturer in 1994. Some of the key areas of his research included fundamental understanding of hydrophilic polymer hydration in relation to their chemical structure variations, factors affecting crystal growth with directly compressible paracetamol as a model drug, formulation and processing of multiparticulate systems. Ali progressed in Liverpool John Moores University through Sr. Lecturer and then to a Reader position before he moved from academia into pharmaceutical industry i.e. Colorcon, in 2000.
Prof Malcom Rowland
Rowland is Professor Emeritus and formerDean, School of Pharmacy and Pharmaceutical Sciences, and member and former director (1996-2000), Centre for Applied Pharmacokinetic Research, University of Manchester. He is a Member, Governing Board, EU Network of Excellence in Biosimulation (Biosim); adjunct professor, University of California San Francisco; advisor to EMEA; Founder member of NDA Partners, and was President, EUFEPS (European Federation for Pharmaceutical Sciences, 1996-2000) and Vice-President FIP (International Pharmaceutical Federation, 2001- 2008). He received his degree in Pharmacy and PhD, University of London, and was on faculty, School of Pharmacy, University of California San Francisco (1967-75) before taking up a professorship at Manchester. He has been awarded honorary doctorate degrees from the University of Poitiers (France) and Uppsala (Sweden), and Honorary Membership, Royal College of Physicians (London). He received the 2007 ACCP Distinguished Investigator Award, the Millennial Pharmaceutical Scientist Award (FIP BPS, 2000), and 1994 AAPS Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism. He has been awarded fellowship of the Academy of Medical Sciences, ACCP (Hon), the Royal Pharmaceutical Society of Great Britain, AAPS, and the Institute of Mathematics. In 2002 he was rated among the top 200 most cited pharmacologists worldwide by the Institute of Scientific Information. His main research interest is physiologically based pharmacokinetics and its application to drug discovery, development and use. He is author of over 300 scientific articles, and coauthor with Thomas Tozer of the textbooks Clinical Pharmacokinetics: Concepts and Applications, and Introduction to Pharmacokinetics and Pharmacodynamics. He was editor of the Journal of Pharmacokinetics and Pharmacodynamics (Formerly Journal of Pharmacokinetics and Biopharmaceutics; 1973-2007), and has established European and U.S.A. pharmacokinetic workshops.
Prof John Staniforth
John N. Staniforth, BSc, PhD, MRPharmS, FZS, CChem, FRSC has been Chief Scientific Officer of Vectura Ltd., (a biosciences company in the United Kingdom) since September 1999. Dr. Staniforth is the Co-Inventor of Penwest's TIMERx technology. Dr. Staniforth served as a Consultant to Penwest Pharmaceuticals Co. Dr. Staniforth is an Honorary Professor of the University of Bath in Bath, England. Dr. Staniforth serves as scientific advisor to a number of international pharmaceutical ... companies and has extensive teaching and research experience, chiefly at the University of Bath, Department of Pharmacy, at Rutgers University and Cornell University in the United States, and at Monash University in Australia. Prior to joining Vectura, Dr. Staniforth served as Professor of Pharmaceutics Technology at the University of Bath from 1980 to 1999. Dr. Staniforth served as Chief Scientific Officer of Vectura Group Plc until June 9, 2004. He serves as a Member of the Industry Advisory Board at Avantium Technologies B.V. Dr. Staniforth serves as a Director of PharmaKodex Ltd. and Halation Ltd. He served as a Director of Penwest Pharmaceuticals Co. since December 1998. His research into powder mixing technology has been widely published and Dr. Staniforth is the recipient of numerous scientific awards, including the Churchill Fellowship, the Pfizer Medal for Pharmaceutical Research and the Special Upjohn Award for research in the field of microwave and radio-frequency drying, and has been elected Fellow of the American Association of Pharmaceutical Sciences. Dr. Staniforth is also the recipient of the 2003 AstraZeneca Industrial Achievement Award. Dr. Staniforth received a BSc in pharmacy from Aston University, Birmingham and a Ph.D. in pharmaceutics from Aston University.
Prof Howard Stevens
Howard Stevens graduated with a BPharm degree from London University in 1967 followed by a PhD from Heriot-Watt University in 1970. In 1970 he entered the pharmaceutical industry and worked initially at The Boots Company (1970-74), then at ER Squibb & Sons (1974-78) before taking up the post of Head of Pharmaceutical Development with Synthèlabo in Paris in 1978. Ten years later he returned to the UK to take up a board position with PolySystems Ltd (the company was later acquired and transformed into Scherer DDS Ltd). In 1995 he was appointed professor of Drug Delivery at Strathclyde University and was awarded a Pfizer Personal Chair in 1998. He is a Member of RPSGB (1971) and was made a Fellow in 1998. He is also a Fellow of the Royal Society of Chemistry. He served as Chairman of APSGB from 2001-2002. At Strathclyde, Professor Stevens leads a drug delivery research group of post-graduate and post-doctoral scientists, undertaking research in nasal delivery using bioadhesive lyophilised systems and in oral controlled release formulations. He is particularly interested in the in-vivo performance of formulations in both man and animal models and is founder and Chairman of Bio-Images Research Ltd, a spin-out company devoted to investigational research on the fate of pharmaceutical preparations in-vivo.
Dr David Tainsh
David is a Pharmacist with over 30 years of industrial experience in the development of New Chemical Entities and has had personal involvement with bringing more than 30 products to market. He was appointed Global Head of Pharmaceutical Development at GlaxoSmithKline in 2006 and Product Development in 2010. Passionate about the industrialisation of pharmaceutical science, he has championed the development of novel methods of manufacture and control. He is a joint patent holder for Liquid Dispensing Technology - a transformative methodology for the preparation and control of ultra low dose products. In 2011 he was appointed to a new corporate position of Chief Product Quality Officer with oversight responsibility for the governance and control framework of Product Quality across GSK for all medicines, vaccines and consumer products. He is a graduate of the Heriot-Watt University and the School of Pharmacy, University of London. He is a Fellow of the School of Pharmacy and of the Royal Pharmaceutical Society.
Prof David Thurston
Professor David Thurston is Professor of Anticancer Drug Discovery, Director of the Cancer Research UK Protein-Protein Interactions Drug Discovery Research Group and Head of the Department of Pharmaceutical & Biological Chemistry. He is also Chief Scientific Advisor to the University spin-out company Spirogen Ltd. Professor Thurston originally trained as a pharmacist at the University of Portsmouth, completing his clinical pre-registration studies at Charing Cross Hospital in London (UK). He then undertook PhD-level medicinal chemistry studies on the chemistry of anti-inflammatory agents through a CASE Award with Glaxo Ltd (now GlaxoSmithKline) supervised by Dr Roger Newton. After postdoctoral studies in the area of anticancer drug design with Professor Laurence Hurley, first at the University of Kentucky (USA) from 1980-1982 and then at the University of Texas at Austin (USA) from 1983-1986, he returned to the UK in 1987 to establish his own research program at the School of Pharmacy, University of Portsmouth, where he was awarded a Readership in 1992 and a Personal Chair in Medicinal Chemistry in 1994. In 1998 he moved to the Department of Pharmaceutical Sciences at the University of Nottingham to become Professor of Cancer Chemotherapy. During this period he co-founded the gene targeting company Spirogen Ltd. In 2001 he joined The School of Pharmacy London as Professor of Anticancer Drug Discovery. He is also a member of the School's Centre for Cancer Medicines. Professor Thurston has been a member of several national committees including the Projects Committee of Cancer Research UK (CR-UK) and the CR-UK New Agents Committee which oversees the acceptance of novel antitumour agents for development and clinical trial. He has also been a member of the Grants Committee of the Association for International Cancer Research (AICR) and a member of the Committee on Safety of Medicines (CSM) which advises the Government on the granting of licenses for new drugs for prescription use and for sale to the public. He has also chaired the Chemistry, Pharmacy & Standards (CPS) Sub-Committee of the CSM. Professor Thurston was a member of the national panels for Unit 9 (Pharmacy) during both the 1992 and 1996 UK Research Assessment Exercises (RAEs). He has been a Director of the Academy of Pharmaceutical Sciences (APS) and is a past member of the APS Executive Committee. He was Conference Science Chairman for the 2006 British Pharmaceutical Conference (BPC). To date Professor Thurston has supervised over 50 postdoctoral research fellows and PhD students, is author of over 100 publications in medicinal chemistry/chemistry journals and books, and is frequently invited to speak at national and international conferences and to give presentations in the research departments of other universities. His recently published textbook, “Chemistry and Pharmacology of anticancer Drugs” has been well-received by the cancer research community and is becoming increasingly recognised as a standard text in the area for undergraduates, postgraduates and cancer researchers in both industry and academia. His research has been funded from a variety of sources including the Research Councils, Cancer Research UK, the British Council and various pharmaceutical companies. In 1996 his funding from Cancer Research UK was awarded Programme Grant status. While overseeing both the chemical and biological research operations of the Cancer Research UK Gene Targeted Drug Design Research Group and Spirogen Ltd, his background in pharmacy enables him to contribute to other areas of the pharmaceutical sciences ranging from drug stability, formulation, delivery, pharmacokinetics and pharmacodynamics, to molecular biology and cellular pharmacology. In particular, he has been closely involved with the discovery and development of the experimental cancer chemotherapy agent SJG-136 which is licensed to Ipsen Pharma and is presently in clinical trials in both the UK and USA. Professor Thurston is also a practicing pharmacist maintaining a competency in community practice. He has trained to practice a number of advanced services such as Medicines Use Reviews (MURs) and Emergency Hormonal Contraception, and is presently completing a postgraduate diploma in Community Pharmacy (PgD Pharm).
Prof Ijeoma Uchegbu
Ijeoma Uchegbu holds a Chair in Pharmaceutical Nanoscience at the School of Pharmacy, University of London and is Director of Postgraduate Research Studies at the School. Ijeoma obtained her PhD from the School of Pharmacy, University of London in 1994, was appointed to a lectureship within the Department of Pharmaceutical Sciences, Strathclyde University in 1997 and a Chair in Drug Delivery at Strathclyde University in 2002. In 2006 Ijeoma was appointed to the Chair in Pharmaceutical Nanoscience at the School of Pharmacy, University of London. Ijeoma’s research in pharmaceutical nanoscience has provided insights into nanoparticle design for drug delivery, producing nanosystems (nanomedicines) that promote oral drug absorption and drug transport to the brain for example. Ijeoma and Andreas Schätzlein have also designed an anti-cancer gene medicine that is currently in pre-clinical development. Ijeoma is the Science Secretary of the CRS, a US based learned society with over 2,000 members and with interests in the delivery of pharmaceuticals, former Chair of the Academy of Pharmaceutical Sciences of Great Britain and is the Academia Expert on the Department for Innovation University and Skills’ Science Engineering and Technology Strategy for Women Expert Group. Ijeoma has been awarded various prizes for her work, the latest of which is the Department for Innovation University and Skills’ Women of Outstanding Achievement in Science Engineering and Technology award. Ijeoma along with five other awardees took part in a national photographic exhibition in 2007 at various venues including the Science Museum and the British Museum. Ijeoma is the editor of two books and over 70 patents, patent applications, peer reviewed journal articles and book chapters.
Prof Clive Wilson
Prof Peter York
Professor York has a background and broad experience in the areas of pharmaceutical material science and processing, and the design and evaluation of drug delivery systems. Over recent years his research focus has been in crystal engineering and particle design of drugs using supercritical fluid technologies, in silico tools for knowledge engineering, and the modernisation of Chinese traditional medicine. Dr York has published widely in these fields and holds numerous patents and has consulted widely. He has been a member of various pharmacopoeia and regulatory committees in the UK and Europe and currently acts as an expert advisor to the MHRA and WHO. Dr York has also been a co-founder of several start-up hi-tech university companies and in 2008 Professor York was honoured as a Visiting Professor at the Shanghai Institute of Materia Medica.
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.